Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept

Condition:   Neovascular Age-related Macular Degeneration Intervention:   Drug: Brolucizumab 6 mg solution for intravitreal injection Sponsors:   Vista Klinik;   Novartis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials